LAS VEGAS, Jan. 13 Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, for families nationwide and internationally, today reviewed its 2010 business strategies in an interview of Matthew Schissler, co-founder and CEO, by analyst Francis Gaskins.
The entire interview is available at http://gaskinsco.com/cbai-1-12-10.mp3
Mr. Schissler said the recent CBAI news that its new Las Vegas laboratory will be storing stem cells for a major Latin America firm shows that Cord Blood America has diversified its revenue stream and is no longer solely reliant on its own cord blood storage service. Cord Blood America's co-founder said retirement of more than $10 million in debt in 2009 means the initial balance sheet made public in 2010 will be much improved.
Cord Blood America's CEO also stressed that the Company has the funds in place for acquisitions in 2010 and believes the market is right to add companies to the Cord Blood America family. "We have in place investor-friendly financing, debt that can be paid back in cash rather than stock," Mr. Schissler said.
Mr. Schissler stressed in the interview the three pillars of success for Cord Blood America in 2010: organic growth, acquisitions, and diversification of the revenue stream.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 [email protected]
SOURCE Cord Blood America, Inc.